Accustem Sciences Inc. financial data

Symbol
ACUT on OTC
Industry
Pharmaceutical Preparations
Location
5 Penn Plaza, 19 Th Floor, #1954, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
AccuStem Sciences Ltd (to 7/1/2021)
Latest financial report
10-Q - Q2 2024 - Sep 16, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.63 % -91.6%
Debt-to-equity -106 % +65.2%
Return On Equity 69.4 % -91%
Return On Assets -1.13K % -200%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.3M shares 0%
Common Stock, Shares, Outstanding 11.3M shares 0%
Entity Public Float 16M USD +416%
Common Stock, Value, Issued 11.3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 11.3M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 11.3M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 174K USD -21.3%
General and Administrative Expense 1.47M USD -48.5%
Operating Income (Loss) -1.65M USD +46.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.65M USD +46.5%
Net Income (Loss) Attributable to Parent -1.65M USD +46.5%
Earnings Per Share, Basic -0.15 USD/shares +42.3%
Earnings Per Share, Diluted -0.15 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current 29.6K USD
Assets, Current 137K USD -69.6%
Property, Plant and Equipment, Net 2.23K USD -61.9%
Assets 140K USD -69.5%
Accounts Payable, Current 745K USD +94.6%
Accrued Liabilities, Current 155K USD -58.3%
Liabilities, Current 3.02M USD +71.3%
Liabilities 3.02M USD +71.3%
Retained Earnings (Accumulated Deficit) -7.33M USD -29.1%
Stockholders' Equity Attributable to Parent -2.88M USD -121%
Liabilities and Equity 140K USD -69.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -237K USD +46.8%
Net Cash Provided by (Used in) Financing Activities 225K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 11.3M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1K USD +97.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 697 USD -0.71%
Deferred Tax Assets, Valuation Allowance 1.36M USD +55.2%
Depreciation 3.63K USD +0.03%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.79M USD -157%
Property, Plant and Equipment, Gross 11K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 1.23M USD +68.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 4.43M USD +1.65%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.36M USD +55.2%
Share-based Payment Arrangement, Expense 13.9K USD +10.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%